OSELTAMIVIR PHOSPHATE CAPSULES

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

OSELTAMIVIR (OSELTAMIVIR PHOSPHATE)

থেকে পাওয়া:

STRIDES PHARMA CANADA INC

এটিসি কোড:

J05AH02

INN (আন্তর্জাতিক নাম):

OSELTAMIVIR

ডোজ:

45MG

ফার্মাসিউটিকাল ফর্ম:

CAPSULE

রচনা:

OSELTAMIVIR (OSELTAMIVIR PHOSPHATE) 45MG

প্রশাসন রুট:

ORAL

প্যাকেজ ইউনিট:

250ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

NEURAMINIDASE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0139501004; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2020-08-24

পণ্য বৈশিষ্ট্য

_Pr_
_Oseltamivir Phosphate Capsules (oseltamivir phosphate)_
_Page 1 of 45 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
OSELTAMIVIR PHOSPHATE CAPSULES
Capsules, 30 mg, 45 mg and 75 mg oseltamivir (as oseltamivir
phosphate), Oral
USP
Antiviral Agent
Strides Pharma Canada Inc.
1565, Boul. Lionel-Boulet
Varennes, Quebec
Canada J3X 1P7
Date of Initial Authorization:
AUG 24, 2020
Date of Revision:
MAY 31, 2023
Submission Control Number: 270536
_Pr_
_Oseltamivir Phosphate Capsules (oseltamivir phosphate)_
_Page 2 of 45 _
RECENT MAJOR LABEL CHANGES
4 Dosage and Administration
05/2023
7 Warnings and Precautions, 7.1.1 Pregnant Women
05/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
................................................................................................
2
TABLE OF CONTENTS
.................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................................
4
1
INDICATIONS
....................................................................................................................
4
1.1
Pediatrics
........................................................................................................................
5
1.2
Geriatrics
........................................................................................................................
5
2
CONTRAINDICATIONS
.......................................................................................................
5
4
DOSAGE AND ADMINISTRATION
.......................................................................................
5
4.1
Dosing Considerations
....................................................................................................
5
4.2
Recommended Dose and Dosage Adjustment
.............................................................. 6
4.3
Recon